kabutan

Kyowa Kirin Co., Ltd.(4151) Summary

4151
TSE Prime
Kyowa Kirin Co., Ltd.
2,331.0
JPY
+28.0
(+1.22%)
Mar 13, 3:30 pm JST
14.62
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
16.2
PBR
1.37
Yield
3.00%
Margin Trading Ratio
33.62
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
2,295.5 JPY 14.41 USD
Previous Close Mar 12
2,303.0 JPY 14.48 USD
High Mar 13, 3:24 pm
2,340.0 JPY 14.68 USD
Low Mar 13, 9:00 am
2,292.0 JPY 14.39 USD
Volume
2,352,300
Trading Value
5.46B JPY 0.03B USD
VWAP
2320.99 JPY 14.56 USD
Minimum Trading Value
233,100 JPY 1,462 USD
Market Cap
1.23T JPY 7.71B USD
Number of Trades
5,130
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
3,130
1-Year High Mar 5, 2026
12,784
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 34,800 230,500 6.62
Feb 27, 2026 39,400 113,500 2.88
Feb 20, 2026 43,500 119,800 2.75
Feb 13, 2026 34,100 190,900 5.60
Feb 6, 2026 35,800 140,800 3.93
Company Profile
Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Group, focusing on pharmaceutical business and new drug development through its biotechnology division. The company has formed a partnership with Fujifilm.
Sector
Pharmaceuticals
Kyowa Kirin Co., Ltd. primarily engages in the manufacture and sale of prescription pharmaceuticals. The company has numerous subsidiaries and equity-method affiliates, with Kirin Holdings as its parent company. Kyowa Kirin operates globally, with a particular focus on four key markets: Japan, North America, Europe, and Asia-Oceania. The company excels in biopharmaceutical development, possessing a unique drug discovery platform centered on antibody drug development and manufacturing technologies. Kyowa Kirin concentrates on creating new drugs that address unmet medical needs, particularly in disease areas such as nephrology, oncology, and immunology-allergy.